SCHEMBL715529

SCHEMBL715529

Cc1cccc2cc(C(C)N)c(N3CCN(C(=O)C4CC4)CC3)nc12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.47
TSHR P16473 4/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
LMNA P02545 3/20 0.44
POLB P06746 1/20 0.44
ALDH1A1 P00352 4/20 0.43
KDM4E B2RXH2 3/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
MTNR1B P49286 1/20 0.42
THRB P10828 1/20 0.42
PIK3CD O00329 2/20 0.42
TNKS O95271 1/20 0.41
TP53 P04637 3/20 0.41
USP2 O75604 1/20 0.41
CLK1 P49759 1/20 0.41
ALOX15 P16050 1/20 0.40
CASP1 P29466 1/20 0.40
CASP7 P55210 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL715528 1.00 MAPT (0.47) MAPTTSHRMEN1KMT2ANPSR1
SCHEMBL714883 0.90 MAPT (0.51) MAPTTSHRMEN1KMT2ANPSR1
SCHEMBL714882 0.90 MAPT (0.51) MAPTTSHRMEN1KMT2ANPSR1
SCHEMBL717259 0.87 PIK3CD (0.53) MAPTTSHRMEN1KMT2AALDH1A1
SCHEMBL717258 0.87 PIK3CD (0.53) MAPTTSHRMEN1KMT2AALDH1A1
SCHEMBL17530802 0.83 SOS1 (0.42) MAPTTSHRMEN1KMT2ANPSR1
SCHEMBL17530801 0.83 SOS1 (0.42) MAPTTSHRMEN1KMT2ANPSR1
SCHEMBL15875832 0.82 PIK3CD (0.44) MAPTLMNAALDH1A1MTNR1BTHRB
SCHEMBL15875835 0.82 PIK3CD (0.44) MAPTLMNAALDH1A1MTNR1BTHRB
SCHEMBL845236 0.81 ALOX15 (0.59) MAPTTSHRNPSR1POLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2403847-B1 TRIAZINE DERIVATIVES AS KINASE INHIBITORS UCB BIOPHARMA SPRL (BE) 2016-03-02 EP disclosed
US-8785628-B2 Triazine derivatives as kinase inhibitors UCB PHARMA, S.A. (BE) 2014-07-22 US disclosed
US-20120053167-A1 Triazine Derivatives as Kinase Inhibitors UCB PHARMA, S.A. (BE) 2012-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053167-A1 Triazine Derivatives as Kinase Inhibitors MAP3K15, PI4KA, MAP3K20 MAPT 1229/4885TSHR 931/4885MEN1 3000/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.